일양약품

007570KOSPI의약품 제조업

47.5 / 100

Reference Date: 2026-07-24

Financial Score12.0 / 40

News Sentiment17.5 / 25

Momentum6.0 / 20

Disclosure12.0 / 15

AI Analysis: PBR is undervalued vs. peers but Operating Profit is on a declining trend. Rose 6.4% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Ilwang Pharm focuses on developing innovative drugs like 'Noltek' (ulcer treatment) and 'Sufekt' (leukemia treatment), expanding into global markets, and strengthening long-term growth through R&D investments. In 2022, the company reported consolidated sales of 2.724 trillion KRW and operating profit of 49 billion KRW, with ongoing market expansion in China and Mexico.

Number of Employees

665people

Average Salary

84.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

21.68Industry Average 11.231.5Point

1.9x industry avg (risky)

PBR

0.64Industry Average 0.814.0Point

In line with industry avg

ROE

2.97Industry Average 4.012.5Point

Below industry avg

Debt Ratio

18.54Industry Average 12.432.0Point

Higher than industry avg (caution)

Trend 2023~20252.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲0.3% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼43.9% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 2.2% (improving, 3yr)

Detailed News Sentiment

12 totalPositive 5Neutral 4Negative 3Average Sentiment Score 70

Neutral
GC녹십자의료재단, ISO 45001 인증 획득
GC녹십자의료재단의 ISO 45001 인증 획득은 해당 기관의 안전 및 보건 관리 시스템 강화를 의미하지만, 일양약품 주식에 직접적인 영향은 제한적입니다.
Positive
[단독]일양약품, 오너 가족회사 '대방기획' 청산 완료…경영쇄신 마침....
일양약품의 가족회사 청산 완료로 경영 효율성 향상과 윤리적 리스크 해소가 기대되어 긍정적 영향.
Neutral
GC메디아이 미소몰닷컴, 독감 백신 사전주문 프로모션
일양약품 관련 직접적인 영향 없음, 주로 의료용품 온라인 쇼핑몰의 프로모션 정보 제공.

Detailed Momentum

52-week position1.0Point

Near 52w low (12%, downtrend)

Current 8,130Won52-week high 13,75052-week low 7,320

1-month return4.0Point

1m +6.41% (slight rise)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

4 totalPositive 1Neutral 3Negative 0

Neutral임원ㆍ주요주주특정증권등거래계획보고서2026-06-30
Neutral임원ㆍ주요주주특정증권등거래계획보고서2026-06-30
Neutral[기재정정]타법인주식및출자증권취득결정2026-06-30
Positive[기재정정]단일판매ㆍ공급계약체결2026-06-30